Yanpeng Zhang

Hangzhou, 310000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Identification of a new pseudogenes/lncRNAs-hsa-miR-26b-5p-COL12A1 competing endogenous RNA network associated with prognosis of pancreatic cancer using bioinformatics analysis.

Identification of a new pseudogenes/lncRNAs-hsa-miR-26b-5p-COL12A1 competing endogenous RNA network associated with prognosis of pancreatic cancer using bioinformatics analysis.

Journal: Aging
Published: March 01, 2020

ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1.

ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1.

Journal: Molecular cancer
Published: February 10, 2020

Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy.

Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy.

Journal: American journal of translational research
Published: September 28, 2019

ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis.

ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis.

Journal: Oncogenesis
Published: July 30, 2019

miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5.

miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5.

Journal: International journal of biological sciences
Published: February 14, 2019

WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.

WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.

Journal: Molecular cancer
Published: February 03, 2019

The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.

The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction.

Journal: International journal of biological sciences
Published: June 05, 2018

2-[1-(4-Bromo-phen-yl)-2-nitro-eth-yl]hexa-noic acid.

2-[1-(4-Bromo-phen-yl)-2-nitro-eth-yl]hexa-noic acid.

Journal: Acta crystallographica. Section E, Structure reports online
Published: March 14, 2014
Showing 1-8 of 8

Last Updated: 09/26/2026